Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...
Tag: AMGN
Why Atlanta Tops the Hottest 2023 Real Estate Markets
Atlanta is hot. Georgia’s capital tops the National Association of Realtors’ list of markets to watch in 2023, based on 10 metrics, including housing affordability, employment conditions, and populati...
Amgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billion
Amgen Inc. AMGN, -2.42% said Monday it has agreed to acquire Horizon Therapeutics Plc HZNP, +0.39% in an all-cash deal valued at $27.8 billion, confirming earlier reports and a deal that was first moo...
Horizon Therapeutics, Coupa Software, Rivian, and More Stock Market Movers
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barro...
4 Advisors on Their Top Bond Buys Now
With bonds offering their juiciest yields in years, we queried some wealth management pros on where they see the best fixed-income opportunities now: David Rossmiller, Bessemer Trust: We like longer b...
Stock Market Looks Poised to Rally as Bond Yield Falls
Text size Michael Nagle/Bloomberg The worst may be over for the stock market. Key equity indexes continued their autumn rally, and there could be more gains before the end of the year, helped by conti...
Big Pharma Stocks Are Breaking Out. Here Are Some Winners.
Big pharma stocks are trying to break out to new heights. They have reported more-than-satisfactory earnings and are expecting further progress on new pipelines of drugs. These stocks had been outpe...
Can Amgen Finally Make an Upside Breakout?
Pharmaceutical giant Amgen Inc. (AMGN) has been trading sideways in the $250-$260 area many times since April. The $64,000 question is whether AMGN can stage an upside breakout. Let’s check the ...
Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Pfizer is in advanced talks to buy Global Blood Therapeutics the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its po...
Stocks Are Ready for a Bounce Higher After S&P 500 Closes Above Bear Market
Text size Dreamstime The stock market came awfully close to finishing Friday in a bear market, at least 20% off its peak in early January. Many investors would like to see it get there so Wall Street ...
Stocks for the Recession That May—or May Not—Be Coming
Text size Exelon stock offers a little bit of offense to go with its defense. Dreamstime The yield curve briefly inverted this past week—and that’s a recession signal that is either like Paul Revere’s...